Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real‐world study

Ähnliche Einträge

• Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study
  von: Tatsuhiko Azegami, et al.
  Veröffentlicht: (2025)
• Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
  von: Chi‐Ho Lee, et al.
  Veröffentlicht: (2024)
• Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis
  von: Anat Tsur, et al.
  Veröffentlicht: (2025)
• Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria
  von: Afif Nakhleh, et al.
  Veröffentlicht: (2024)
• Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes
  von: Jingchuan Guo, et al.
  Veröffentlicht: (2024)